RU2012141590A - Соединения для лечения рака - Google Patents

Соединения для лечения рака Download PDF

Info

Publication number
RU2012141590A
RU2012141590A RU2012141590/04A RU2012141590A RU2012141590A RU 2012141590 A RU2012141590 A RU 2012141590A RU 2012141590/04 A RU2012141590/04 A RU 2012141590/04A RU 2012141590 A RU2012141590 A RU 2012141590A RU 2012141590 A RU2012141590 A RU 2012141590A
Authority
RU
Russia
Prior art keywords
compound
cancer
alkyl
specified
tumor
Prior art date
Application number
RU2012141590/04A
Other languages
English (en)
Other versions
RU2581367C2 (ru
Inventor
Джеймс Т. Долтон
Дуэйн Д. Миллер
Суньцзо АН
Цзяньцзунь ЧЭНЬ
Чарльз ДЬЮК
Чиень-Мин ЛИ
Вэй Ли
Янь ЛУ
Чжао ВАН
Original Assignee
Джи Ти Икс, ИНК.
Юниверсити Оф Теннесси Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи Ти Икс, ИНК., Юниверсити Оф Теннесси Рисерч Фаундейшн filed Critical Джи Ти Икс, ИНК.
Publication of RU2012141590A publication Critical patent/RU2012141590A/ru
Application granted granted Critical
Publication of RU2581367C2 publication Critical patent/RU2581367C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

1. Соединение, представленное структурой формулы (II):гдеВ представляет собой-(имидазол);R, R, R, R, Rи Rнезависимо представляют собой атом водорода, O-алкил, O-галогеналкил, F, Cl, Br, I, галогеналкил, CF, CN, -CHCN, NH, гидроксил, -(СН)NHCH, -(CH)NH, -(CH)N(CH), -ОС(O)CF, C-Cлинейный или разветвленный алкил, галогеналкил, алкиламино, аминоалкил, -OCHPh, -NHCO-алкил, СООН, -C(O)Ph, C(O)O-алкил, С(O)Н, -C(O)NHили NO;Rи Rнезависимо представляют собой атом водорода, O-алкил, O-галогеналкил, F, Cl, Br, I, галогеналкил, CF, CN, -CHCN, NH, гидроксил, -(CH)NHCH, -(CH)NH, -(CH)N(CH), -ОС(O)CF, C-Cлинейный или разветвленный алкил, галогеналкил, алкиламино, аминоалкил, -OCHPh, -NHCO-алкил, СООН, -C(O)Ph, С(O)O-алкил, С(O)Н, -C(O)NHили NO;Х представляет собой связь, C-Cуглеводород или О;Y представляет собой связь, -С=О, -C=S, -C=N-NH, -C=N-OH, -СН-ОН, -С=СН-CN; -C=N-CN, -СН=СН-, -С=С(СН), -C=N-OMe, -(C=O)-NH, -NH-(C=O), -(C=O)-O, -O-(С=O), -(CH)-(C=O), (C=O)-(CH), -(SO)-NH-, -NH-(SO)-, SO, SO или S;i представляет собой целое число от 0 до 5;1 представляет собой целое число от 1 до 2;n представляет собой целое число от 1 до 3; иm представляет собой целое число от 1 до 3;2. Соединение по п.1, где указанное соединение представлено структурой формулы V:где R, R, R, n и В соответствуют определениям по п.1.3. Соединение по п.1, где указанное соединение представлено структурой формулы (XVI):где Rи Rнезависимо представляют собой Н, O-алкил, I, Br, Cl, F, алкил, галогеналкил, аминоалкил, -(СН)NHCH, -(CH)NH, -(CH)N(CH), OCHPh, ОН, CN, NO, -NHCO-алкил, COOH, С(O)O-алкил или С(O)Н;Rпредставляет собой I, Br, Cl или F;i представляет собой целое число от 0 до 5; иn равно 1-4.4. Соединение по п.3, где указанный Rпредставляет собой F.5. Соединение по п.3, где указанный Rпредставляет собой Cl.6. Соединение по п.3, где указанный Rпредставляет собой Cl.7. Соединение по п.3, где указанный Rпредставляет собой ОСН.8. Соеди

Claims (24)

1. Соединение, представленное структурой формулы (II):
Figure 00000001
где
В представляет собой
Figure 00000002
-(имидазол);
R1, R2, R3, R4, R5 и R6 независимо представляют собой атом водорода, O-алкил, O-галогеналкил, F, Cl, Br, I, галогеналкил, CF3, CN, -CH2CN, NH2, гидроксил, -(СН2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -ОС(O)CF3, C1-C5 линейный или разветвленный алкил, галогеналкил, алкиламино, аминоалкил, -OCH2Ph, -NHCO-алкил, СООН, -C(O)Ph, C(O)O-алкил, С(O)Н, -C(O)NH2 или NO2;
R10 и R11 независимо представляют собой атом водорода, O-алкил, O-галогеналкил, F, Cl, Br, I, галогеналкил, CF3, CN, -CH2CN, NH2, гидроксил, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -ОС(O)CF3, C1-C5 линейный или разветвленный алкил, галогеналкил, алкиламино, аминоалкил, -OCH2Ph, -NHCO-алкил, СООН, -C(O)Ph, С(O)O-алкил, С(O)Н, -C(O)NH2 или NO2;
Х представляет собой связь, C1-C5 углеводород или О;
Y представляет собой связь, -С=О, -C=S, -C=N-NH2, -C=N-OH, -СН-ОН, -С=СН-CN; -C=N-CN, -СН=СН-, -С=С(СН3)2, -C=N-OMe, -(C=O)-NH, -NH-(C=O), -(C=O)-O, -O-(С=O), -(CH2)1-5-(C=O), (C=O)-(CH2)1-5, -(SO2)-NH-, -NH-(SO2)-, SO2, SO или S;
i представляет собой целое число от 0 до 5;
1 представляет собой целое число от 1 до 2;
n представляет собой целое число от 1 до 3; и
m представляет собой целое число от 1 до 3;
2. Соединение по п.1, где указанное соединение представлено структурой формулы V:
Figure 00000003
где R4, R5, R6, n и В соответствуют определениям по п.1.
3. Соединение по п.1, где указанное соединение представлено структурой формулы (XVI):
Figure 00000004
где R4 и R5 независимо представляют собой Н, O-алкил, I, Br, Cl, F, алкил, галогеналкил, аминоалкил, -(СН2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, OCH2Ph, ОН, CN, NO2, -NHCO-алкил, COOH, С(O)O-алкил или С(O)Н;
R3 представляет собой I, Br, Cl или F;
i представляет собой целое число от 0 до 5; и
n равно 1-4.
4. Соединение по п.3, где указанный R3 представляет собой F.
5. Соединение по п.3, где указанный R3 представляет собой Cl.
6. Соединение по п.3, где указанный R4 представляет собой Cl.
7. Соединение по п.3, где указанный R4 представляет собой ОСН3.
8. Соединение по п.3, где указанный R5 представляет собой атом водорода.
9. Соединение по п.2, где указанное соединение представляет собой (2-(4-хлорфенил)-1H-имидазол-4-ил)(3,4,5-триметоксифенил)метанон (12fa):
Figure 00000005
10. Соединение по п.2, где указанное соединение представляет собой (2-(n-толил)-1H-имидазол-4-ил)(3,4,5-триметоксифенил)метанон (12da):
Figure 00000006
11. Соединение по п.2, где указанное соединение представляет собой (2-(4-бромфенил)-1H-имидазол-4-ил)(3,4,5-триметоксифенил)метанон (34):
Figure 00000007
12. Соединение по п.2, где указанное соединение представляет собой (1-метил-2-(n-толил)-1H-имидазол-4-ил)(3,4,5-триметоксифенил)метанон (12dab):
Figure 00000008
13. Соединение по любому из пп.1-12 или его изомер, фармацевтически приемлемая соль, фармацевтический продукт, таутомер, гидрат, N-оксид или их комбинации.
14. Фармацевтическая композиция, содержащая соединение по п.13 и фармацевтически приемлемый носитель.
15. Способ лечения, подавления, уменьшения тяжести, снижения риска или ингибирования рака, включающий введение соединения по п.13 субъекту, страдающему от рака, в условиях, обеспечивающих эффективное лечение рака.
16. Способ по п.15, в котором указанный рак выбран из группы, состоящей из рака предстательной железы, рака груди, рака яичника, рака кожи, меланомы, рака легких, рака толстой кишки, лейкемии, рака почки, рака ЦНС и их комбинаций.
17. Способ по п.16, в котором указанный рак представляет собой меланому или метастатическую меланому.
18. Способ по п.16, в котором указанный рак представляет собой рак предстательной железы или рак яичника.
19. Способ по п.15, в котором указанное введение осуществляется в комбинации с другим типом противораковой терапии.
20. Способ лечения лекарственно-устойчивой опухоли или опухолей, включающий введение соединения по п.13 субъекту, страдающему от рака, в условиях, обеспечивающих эффективное лечение лекарственно-устойчивой опухоли или опухолей.
21. Способ по п.20, в котором указанная опухоль представляет собой раковую опухоль при меланоме или опухоль при метастатической меланоме.
22. Способ по п.20, в котором указанная опухоль представляет собой опухоль при раке предстательной железы или опухоль при раке яичника.
23. Способ по п.20, в котором указанное введение осуществляется в комбинации с альтернативными типами терапии рака.
24. Способ разрушения раковой клетки, включающий получение соединения по п.13 и контактирование раковой клетки с данным соединением в условиях, обеспечивающих эффективное уничтожение раковой клетки.
RU2012141590/04A 2010-03-01 2010-12-29 Соединения для лечения рака RU2581367C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30936010P 2010-03-01 2010-03-01
US61/309,360 2010-03-01
US31579010P 2010-03-19 2010-03-19
US61/315,790 2010-03-19
US37667510P 2010-08-24 2010-08-24
US61/376,675 2010-08-24
PCT/US2010/062418 WO2011109059A1 (en) 2010-03-01 2010-12-29 Compounds for treatment of cancer

Publications (2)

Publication Number Publication Date
RU2012141590A true RU2012141590A (ru) 2014-04-10
RU2581367C2 RU2581367C2 (ru) 2016-04-20

Family

ID=44542481

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012141590/04A RU2581367C2 (ru) 2010-03-01 2010-12-29 Соединения для лечения рака

Country Status (11)

Country Link
US (1) US9334242B2 (ru)
EP (2) EP2542081A4 (ru)
JP (1) JP5879273B2 (ru)
KR (2) KR20120130777A (ru)
CN (2) CN104592205A (ru)
AU (1) AU2010347233B2 (ru)
CA (1) CA2791738C (ru)
IL (3) IL221710A (ru)
MX (1) MX2012010115A (ru)
RU (1) RU2581367C2 (ru)
WO (1) WO2011109059A1 (ru)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2927660T3 (es) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
KR20120130777A (ko) * 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
AU2011293353B2 (en) * 2010-08-24 2015-02-26 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
NZ628969A (en) 2012-02-17 2017-03-31 Millennium Pharm Inc Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
EA201791271A1 (ru) 2012-05-31 2018-01-31 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
US20150166528A1 (en) 2012-06-14 2015-06-18 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
CA2916468C (en) 2013-07-02 2019-07-23 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
CN103755664B (zh) * 2014-01-22 2016-08-17 沈阳药科大学 4-芳基噻（硒）唑类化合物及其用途
CN106132422A (zh) 2014-02-27 2016-11-16 莱斯拉公司 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法＆相关治疗方法
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CN103864785B (zh) * 2014-03-11 2015-12-09 中国农业大学 一类氮杂吲哚骨架的噻唑啉衍生物及其制备方法与应用
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
WO2015168286A1 (en) 2014-04-30 2015-11-05 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MX2016014559A (es) * 2014-05-06 2018-02-19 Gtx Inc Compuestos para el tratamiento de cancer.
CN103980248B (zh) * 2014-05-10 2015-11-18 浙江大学 3,5-二取代-4-氨基噻吩-2-甲醛化合物及其制备方法
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP2018510135A (ja) 2015-02-11 2018-04-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
EP3288384A4 (en) * 2015-05-01 2019-01-23 Georgia State University Research Foundation BENZHYDROL DERIVATIVES FOR ADMINISTERING CONDITIONS RELATED TO HYPOXIC INDUCIBLE FACTORS
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
EP3368539B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Substituted indazole compounds as ror gamma t inhibitors and uses thereof
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN106279027A (zh) * 2016-07-26 2017-01-04 沈阳药科大学 (1‑芳基‑1h‑吡唑‑4‑基)(3,4,5‑三甲氧基苯基)甲酮、甲酮肟类化合物及其用途
CN106187923A (zh) * 2016-08-01 2016-12-07 沈阳药科大学 2‑芳基‑4‑芳酰基‑三氮唑类化合物及其用途
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
WO2019002074A1 (en) 2017-06-29 2019-01-03 Bayer Aktiengesellschaft THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PRMT5
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
CN109180649B (zh) * 2017-08-18 2021-03-12 四川百利药业有限责任公司 一种含吲哚环的ido抑制剂及其制备方法
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CA3078769A1 (en) 2017-10-27 2019-05-02 Boehringer Ingelheim International Gmbh Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
CN108358864B (zh) * 2017-12-15 2020-07-17 五邑大学 一种2-酰基-5-苯基噁唑类微管蛋白抑制剂的制备方法及应用
WO2019222385A1 (en) * 2018-05-15 2019-11-21 University Of Tennessee Research Foundation Compounds for treatment of triple negative breast cancer and ovarian cancer
CA3099922A1 (en) * 2018-05-15 2019-11-21 University Of Tennessee Research Foundation Compounds for treatment of pancreatic cancer
CN109020904B (zh) * 2018-06-15 2021-05-25 沈阳药科大学 2-芳基-4-芳酰基-5-脂环胺基-2h-三氮唑类化合物及其用途
BR112020026783A2 (pt) 2018-06-29 2021-03-30 Forma Therapeutics, Inc. Inibição da proteína de ligação creb (cbp)
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN109503509B (zh) * 2018-12-17 2021-10-19 湘潭大学 4-苯乙烯基噻唑及衍生物及其合成方法
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN112142711B (zh) * 2019-06-28 2022-03-29 中国科学院上海药物研究所 取代噻吩类化合物、其制备方法及其用途
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
KR102346187B1 (ko) * 2019-12-26 2021-12-31 울산과학기술원 디히드로퓨란 유도체 및 이의 합성 방법
WO2021203100A1 (en) * 2020-04-03 2021-10-07 Veru Inc. Methods of treating coronavirus
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN113620930B (zh) * 2021-07-12 2022-08-16 南京烁慧医药科技有限公司 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用
CN113929591A (zh) * 2021-10-09 2022-01-14 中国科学技术大学 具有抗增殖活性的抑制剂
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN114751891B (zh) * 2022-04-27 2023-04-07 广东晨康生物科技有限公司 一种(2-(1h-吲哚-3-基)-1h-咪唑-4-基)苯基甲酮类化合物及其应用
CN114805307A (zh) * 2022-04-29 2022-07-29 南京雷正医药科技有限公司 一种用于制备冠状病毒治疗药物的吲哚类化合物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH528514A (de) * 1969-05-22 1972-09-30 Bayer Ag Verfahren zur Herstellung von Acylimidazolen
US4721712A (en) 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
US4609670A (en) * 1984-11-13 1986-09-02 Eli Lilly And Company Imidazolium hypoglycemic agents
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
CA2396738C (en) 1990-11-30 2006-08-29 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
NO924963L (no) 1991-12-27 1993-06-28 Sankyo Co Pyridyltiazolidinkarboksylsyreamid-derivater og fremgangsmaate til fremstilling derav
JP3393891B2 (ja) 1992-08-18 2003-04-07 塩野義製薬株式会社 イミダゾール類の製造方法
US5514690A (en) 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
DK0798298T3 (da) 1994-12-15 2001-10-22 Sankyo Co Thiazolidinon- eller oxazolidonderivater til behandling af angina pectoris eller sammensætninger indeholdende samme som aktiv bestanddel
CZ290989B6 (cs) 1995-03-02 2002-11-13 Sankyo Company, Limited Opticky aktivní thiazolidinonový derivát, prostředek jej obsahující, pouľití tohoto derivátu a způsob jeho přípravy
JP2004067510A (ja) 1997-12-26 2004-03-04 Mitsubishi Pharma Corp 新規イミダゾール誘導体
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2001017992A1 (en) 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001240593A (ja) 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
ES2237482T3 (es) 1999-12-27 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados de aminoalquilamidas sustituidas como antagonistas de la hormona estimuladora de los foliculos.
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
EP1381602A1 (en) 2001-04-19 2004-01-21 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
EP1432706A2 (en) 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
CA2463441A1 (en) 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
AU2002352706A1 (en) 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
CN1633420A (zh) 2002-04-08 2005-06-29 托伦脱药品有限公司 噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途
WO2003090680A2 (en) 2002-04-23 2003-11-06 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
WO2004052280A2 (en) * 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
WO2004072068A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN1747936A (zh) 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
CN1826111A (zh) 2003-04-10 2006-08-30 阿文尼尔药品公司 用于治疗变应性和过增生性疾病的咪唑衍生物
EP1636183A1 (en) 2003-05-16 2006-03-22 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
CN1826310B (zh) 2003-07-24 2010-07-21 利奥制药有限公司 新的氨基二苯酮化合物
WO2005014534A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
MXPA06005528A (es) 2003-11-18 2007-01-30 Univ Tennessee Res Foundation Tiazolidinona-amidas, amidas de acido tiazolidina-carboxilico, metodos de elaboracion, y uso de las mismas.
US20060014740A1 (en) 2003-11-18 2006-01-19 Miller Duane D Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CN1938023A (zh) 2004-03-08 2007-03-28 惠氏公司 离子通道调节剂
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
EP2298291A3 (en) 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
KR100889721B1 (ko) 2004-08-17 2009-03-23 에프. 호프만-라 로슈 아게 치환 히단토인
US20060211603A1 (en) 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
EP1627876A1 (en) 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
PL1828148T3 (pl) 2004-12-13 2010-08-31 Leo Pharma As Triazol podstawiony związkami aminobenzofenonu
US7459564B2 (en) 2005-01-13 2008-12-02 Bristol-Myers Squibb Company Substituted biaryl compounds as factor XIa inhibitors
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
EP1926487A2 (en) 2005-07-19 2008-06-04 University of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
EA016300B1 (ru) 2005-07-29 2012-04-30 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
CA2625974A1 (en) 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives for the treatment of anxiety and related diseases
PL1954684T3 (pl) 2005-11-15 2014-10-31 Otsuka Pharma Co Ltd Związek oksazolowy i kompozycja farmaceutyczna
KR101081293B1 (ko) 2006-01-18 2011-11-08 에프. 호프만-라 로슈 아게 11 베타-에이치에스디1 억제제로서 티아졸
EP1832585A1 (en) 2006-03-10 2007-09-12 ORIDIS BIOMED Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives for treatment of hyperproliferative diseases
EP1834954A1 (en) 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
WO2007115805A2 (en) 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
KR20090033436A (ko) 2006-07-13 2009-04-03 바이엘 크롭사이언스 소시에떼아노님 살진균제 히드록시모일-테트라졸 유도체
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
DK2050749T3 (en) 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
CA2665804A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
JP2010502706A (ja) 2006-09-07 2010-01-28 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害活性を有するフェネチルアミド誘導体
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
JP2010513519A (ja) 2006-12-22 2010-04-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼインヒビター活性を有するある種のピラゾリン誘導体
WO2008128179A1 (en) 2007-04-14 2008-10-23 The University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
US20090142832A1 (en) 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
ES2927660T3 (es) * 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
KR101134194B1 (ko) 2009-12-03 2012-04-09 서울대학교산학협력단 헤테로바이아릴피리딘 유도체 화합물의 제조방법 및 이러한 방법에 의해 제조된 헤테로바이아릴피리딘 유도체 화합물
KR20120130777A (ko) 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as AKT kinase inhibitors

Also Published As

Publication number Publication date
CN104592205A (zh) 2015-05-06
KR20180038079A (ko) 2018-04-13
IL261852A (en) 2018-10-31
IL239672A0 (en) 2015-08-31
EP3064204A1 (en) 2016-09-07
CA2791738C (en) 2020-06-09
US9334242B2 (en) 2016-05-10
AU2010347233B2 (en) 2015-06-18
KR20120130777A (ko) 2012-12-03
EP2542081A4 (en) 2013-07-31
MX2012010115A (es) 2013-02-26
WO2011109059A1 (en) 2011-09-09
CN102883607B (zh) 2015-07-22
US20110257196A1 (en) 2011-10-20
IL221710A (en) 2015-06-30
CN102883607A (zh) 2013-01-16
JP5879273B2 (ja) 2016-03-08
KR101939704B1 (ko) 2019-01-17
RU2581367C2 (ru) 2016-04-20
EP2542081A1 (en) 2013-01-09
IL261852B (en) 2020-09-30
AU2010347233A1 (en) 2012-09-27
JP2013521281A (ja) 2013-06-10
CA2791738A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
RU2012141590A (ru) Соединения для лечения рака
JP2013521281A5 (ru)
RU2013112871A (ru) Соединения для лечения рака
RU2016147654A (ru) Соединения для лечения рака
JP2013538213A5 (ru)
JP2008535902A5 (ru)
JP2014520898A5 (ru)
JP2013199483A5 (ru)
JP2014534200A5 (ru)
JP2017509689A5 (ru)
RU2015142102A (ru) Соединение для лечения рака
RU2015143542A (ru) Ингибиторы jak2 и alk2 и способы их использования
JP2011509949A5 (ru)
RU2010126056A (ru) Органические соединения
WO2011141716A3 (en) Modulators of chk-1 activity
JP2009534408A5 (ru)
JP2011511095A5 (ru)
MX2010001745A (es) Imidazoles fusionados para el tratamiento del cancer.
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP2013503139A5 (ru)
WO2006001967A3 (en) Migrastatin analogs in the treatment of cancer
JP2009519907A5 (ru)
RU2008106949A (ru) Бензимидазолы применимые в качестве ингибиторов протеинкиназ
JP2009520692A5 (ru)
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos